zacks.com
Merck (MRK) Stock Dips While Market Gains: Key Facts
In the latest trading session, Merck (MRK) closed at $121.41, marking a -1.95% move from the previous day.
Merck & Co., Inc.MRKNYSE
Loading
Latest News
Loading news...
zacks.com
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
defenseworld.net
Becker Capital Management Inc. Has $25.12 Million Stock Position in Merck & Co., Inc. $MRK
Becker Capital Management Inc. lessened its stake in Merck and Co., Inc. (NYSE: MRK) by 2.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 296,427 shares of the company's stock after selling 7,498 shares during the quarter. Becker
defenseworld.net
Bright Futures Wealth Management LLC. Buys Shares of 5,628 Merck & Co., Inc. $MRK
Bright Futures Wealth Management LLC. purchased a new position in shares of Merck and Co., Inc. (NYSE: MRK) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 5,628 shares of the company's stock, valued at approximately $472,000. Other hedge funds and other institutional
defenseworld.net
Davis R M Inc. Lowers Stake in Merck & Co., Inc. $MRK
Davis R M Inc. lessened its stake in Merck and Co., Inc. (NYSE: MRK) by 32.7% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,404 shares of the company's stock after selling 12,850 shares during the period. Davis R M Inc.'s
defenseworld.net
111 Capital Has $1.71 Million Holdings in Merck & Co., Inc. $MRK
111 Capital increased its position in Merck and Co., Inc. (NYSE: MRK) by 48.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,391 shares of the company's stock after buying an additional 6,685 shares during the period. 111 Capital's holdings in Merck and
defenseworld.net
Merck & Co., Inc. $MRK Shares Sold by Diversify Wealth Management LLC
Diversify Wealth Management LLC lowered its position in shares of Merck and Co., Inc. (NYSE: MRK) by 63.9% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 13,731 shares of the company's stock after selling 24,300 shares during the period. Diversify Wealth Management LLC's holdings in
businesswire.com
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients With Earlier-Stage RCC.
businesswire.com
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--WELIREG Plus LENVIMA Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated RCC Patients.
defenseworld.net
Merck & Co., Inc. $MRK Shares Purchased by American Century Companies Inc.
American Century Companies Inc. increased its stake in shares of Merck and Co., Inc. (NYSE: MRK) by 20.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,559,640 shares of the company's stock after buying an additional 787,181 shares
defenseworld.net
Banco Santander S.A. Reduces Stake in Merck & Co., Inc. $MRK
Banco Santander S.A. lessened its position in shares of Merck and Co., Inc. (NYSE: MRK) by 58.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 155,068 shares of the company's stock after selling 216,463 shares during the quarter. Banco Santander
defenseworld.net
Artisan Partners Limited Partnership Increases Position in Merck & Co., Inc. $MRK
Artisan Partners Limited Partnership raised its position in shares of Merck and Co., Inc. (NYSE: MRK) by 2.6% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,334,597 shares of the company's stock after buying an additional 33,849 shares during
reuters.com
Merck to lay off around 150 employees at US site amid slump in Gardasil sales
Merck will lay off about 150 employees across its facility in North Carolina that manufactures its human papillomavirus vaccine, Gardasil, according to a notice filed in the state's database this week.
investors.com
Merck Stock, Up 13% In 2026, Ticks Another Box. Is It Now A Buy?
Merck stock ticked another box Friday after the firm said its Keytruda-containing regimen improved outcomes for ovarian cancer patients.
businesswire.com
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, showing that KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab significantly improved overall survival (OS), a key secondary endpoint, for patients with platinum-resistant recurrent ovarian cancer rega.
businesswire.com
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. These late-breaking data will.
defenseworld.net
Merck & Co., Inc. $MRK Shares Sold by Choreo LLC
Choreo LLC trimmed its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 4.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 119,377 shares of the company's stock after selling 5,332 shares during the quarter. Choreo LLC's holdings in
defenseworld.net
DNB Asset Management AS Cuts Holdings in Merck & Co., Inc. $MRK
DNB Asset Management AS lowered its stake in Merck and Co., Inc. (NYSE: MRK) by 0.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 748,427 shares of the company's stock after selling 5,667 shares during the period. DNB Asset
gurufocus.com
Market Today: Nvidia Beats, WBD Bidding War, Uber Air
Guru Stock PicksMS Global Franchise Portfolio has made the following transactions:Reduce in MSCI by 17.11%Sold out in FDSAdd in LSE: EXPN by 13.74%New position i
247wallst.com
Merck Stock Jumps But Reddit Traders Are Getting Cold Feet
A giant in the healthcare space, Merck ( NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a neutral 43 this week.